CompletedPhase 3NCT01535859

Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers

Studying Ovarian hyperstimulation syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: KK Women's and Children's Hospital
Principal Investigator: Marianne Sybille Hendricks, MBBS, MRCOG
KK Women's and Children's Hospital
Intervention: Cabergoline(drug)
Enrollment: 46 target
Eligibility: 21-45 years · FEMALE
Timeline: 2012 – 2016

Study locations (1)

KK Women's and Children's Hospital, Singapore, Singapore

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01535859 on ClinicalTrials.gov

Other trials for Ovarian hyperstimulation syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT07043322
Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome
Tanta University

See all trials for Ovarian hyperstimulation syndrome →

← Back to all trials